11 completed, 4 terminated. 15 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 11, Terminated 4 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Stage IV Marginal Zone Lymphoma: new trials by email Literature Review of Stage IV Marginal Zone Lymphoma trials Research Report on Stage IV Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant ondansetron, survey administration, management of therapy complications - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 49 | 2008-08-08 | 2017-05-23 |
| Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma pegfilgrastim, rituximab, flow cytometry - Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma | Phase 2 | Completed | Roswell Park Cancer Institute | 20 | 2007-04-17 | 2017-10-09 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation - Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome | Phase 2 | Completed | Fred Hutchinson Cancer Center | 210 | 2004-11-01 | 2019-10-30 |
| Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma pharmacological study, rituximab, dexamethasone - Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 32 | 2004-05-01 | 2017-05-22 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer cyclophosphamide, fludarabine phosphate, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 53 | 2002-01-01 | 2017-05-17 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies alemtuzumab, fludarabine phosphate, total-body irradiation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2001-11-01 | 2020-01-29 |
Lymphoma, B-Cell, Marginal Zone (15) · Lymphoma, Follicular (15) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Mantle-Cell (13) · Burkitt Lymphoma (12) · Hodgkin Disease (12) · Lymphoma, Large-Cell, Immunoblastic (12) · Lymphoma, Non-Hodgkin (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Waldenstrom Macroglobulinemia (11) · Leukemia, Myeloid, Acute (9) · Lymphoma, T-Cell, Cutaneous (9) · Mycosis Fungoides (9) · Sezary Syndrome (9)
Hematologic Diseases (15) · Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoma (15) · Lymphoma, B-Cell (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Blood Protein Disorders (14) · Cardiovascular Diseases (14) · Chronic Disease (14) · Disease Attributes (14) · Hemorrhagic Disorders (14)
Rituximab (6) · Tacrolimus (6) · Mycophenolic Acid (5) · Whole-Body Irradiation (5) · fludarabine phosphate (5) · Cyclophosphamide (3) · Peripheral Blood Stem Cell Transplantation (3) · Cyclosporine (2) · Deferasirox (2) · Methotrexate (2) · merphos (2) · Alemtuzumab (1) · Amplified Fragment Length Polymorphism Analysis (1) · Antilymphocyte Serum (1) · Beclomethasone (1)
Fred Hutchinson Cancer Center (7) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · University of Chicago (1) · University of Nebraska (1) · Wake Forest University Health Sciences (1)
United States (15) · Italy (2) · Denmark (1) · Germany (1)
Brenda Sandmaier (2) · David Maloney (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Francisco Hernandez-ILizaliturri (1) · Leona Holmberg (1) · Mary Ann Knovich, MD (1) · Paul Martin (1) · Paul O'Donnell (1) · Pavan Reddy (1) · Robert Bociek, MD (1) · Sonali Smith (1) · Vinod Pullarkat, MD (1)
PMID 32499241, PMID 19900571, PMID 25085357, PMID 40720747
P30CA015704 (3), P01CA018029 (2), P01CA078902 (1), P30CA014599 (1), P30CA036727 (1), P30CA046592 (1), R21CA119519 (1)